Timothy Erick, PhD(@DrTimothyErick) 's Twitter Profileg
Timothy Erick, PhD

@DrTimothyErick

Senior Science Writer, Breast Oncology Center, Dana-Farber Cancer Institute. Views expressed are my own.

ID:2167103556

calendar_today31-10-2013 19:07:49

8,1K Tweets

810 Followers

1,7K Following

Jerome Adams(@JeromeAdamsMD) 's Twitter Profile Photo

Alarming how we're at risk of reversing 60+ years of public health progress and losing thousands of children's lives to measles in just the next 5 years. Let's prioritize vaccination and public health measures to prevent this devastating setback.

Alarming how we're at risk of reversing 60+ years of public health progress and losing thousands of children's lives to measles in just the next 5 years. Let's prioritize vaccination and public health measures to prevent this devastating setback. #VaccinesSaveLives #PublicHealth
account_circle
Adam Rowe(@AdamRoweVO) 's Twitter Profile Photo

Screw a normal voice acting demo, I’m Adam Rowe and this is my
🔥GET WRECKED REEL🔥

Need an actor who can get absolutely obliterated? I’m your man!

Don’t hire someone who’s never taken a hit!

Hire someone who can get knocked down!

But more importantly, who can get back up. 😌

account_circle
Nancy Lin, MD(@nlinmd) 's Twitter Profile Photo

The messaging is so important: the HPV vaccine is an anti-cancer vaccine not just an “STD vaccine”. In 2020, over 600,000 women were diagnosed with cervical cancer and over 340,000 women died worldwide. Preventing cervical cancer is a really big deal !

account_circle
Polyak Lab(@LabPolyak) 's Twitter Profile Photo

We are thrilled to see our IBC clinical trial study is officially out in BreastCancerResearch. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered.
…ast-cancer-research.biomedcentral.com/articles/10.11…

We are thrilled to see our IBC clinical trial study is officially out in @BCRJournal. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered. …ast-cancer-research.biomedcentral.com/articles/10.11…
account_circle
Timothy Erick, PhD(@DrTimothyErick) 's Twitter Profile Photo

I finally started delving deeper into Warren Zevon's catalog. Listened to 'Desperados Under the Eaves' for the first time today. Wow, what a song. The orchestral ending feels like the musical equivalent of an epic poem.

account_circle
Timothy Erick, PhD(@DrTimothyErick) 's Twitter Profile Photo

Breast cancer is a heavy subject, so I am thankful that some researchers come up with creative clinical trial names. For instance, a retrospective study of T-DXd in patients over 70 is called 'TREX-Old.'

account_circle
Paolo Tarantino(@PTarantinoMD) 's Twitter Profile Photo

5-year update from now published on Journal of Clinical Oncology. Impressive benefit with adjuvant abemaciclib in high-risk, node positive, HR+ breast cancer, with ~7% delta in distant relapse free survival. OS still immature, but trending in favor of abema. ascopubs.org/doi/pdf/10.120…

5-year update from #monarchE now published on @JCO_ASCO. Impressive benefit with adjuvant abemaciclib in high-risk, node positive, HR+ breast cancer, with ~7% delta in distant relapse free survival. OS still immature, but trending in favor of abema. ascopubs.org/doi/pdf/10.120…
account_circle
Harold J. Burstein, MD, PhD, FASCO(@DrHBurstein) 's Twitter Profile Photo

The cohort in INAVO120 was quite endocrine resistant. But PFS of 15m for triplet would be longer than 1st line F + palbo (7m) followed by F + capi (7.3m) even w/o the more limited PFS with F + capi in CDK46i-treated cohort (5.5M). If true would suggest triplet should be standard.

account_circle